Venoplasty can be performed safely and successfully in patients with subtotal and total venous occlusion needing additional transvenous electrodes

Funding Acknowledgements

Type of funding sources: None.

Introduction

Lead failure, but also upgrade procedures from pacemaker to implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) can be hampered by venous obstruction occurring in 10-25% of patients with prior transvenous electrodes. A relatively underused technique to overcome venous obstruction are lead percutaneous venous dilation procedures (venoplasty).

Purpose

We aimed to identify the feasibility of venoplasty procedures in two Dutch tertiary referral centers.

Methods

84 consecutive patients where venoplasty was attempted were included in the study and baseline parameters as well as procedural characteristics and complications were recorded. 42% of patients needed replacement of a defective electrode and 58% an upgrade to CRT or from pacemaker to ICD. Venous stenosis was defined as significant (70-90%), subocclusive (90-99%) and occlusive (100%) and the region was divided into three segments: subclavian vein, brachiocephalic vein and junction to the vena cava superior.

Results

The study included 30 pacemaker and 54 ICD patients, 68±12 years old, 80% were male. Body mass index was 26±3, left ventricular ejection fraction 32±12% and eGFR 63±24ml/min/1,73m2. At the time of the procedure, 2,1±0,8 electrodes were present and 1,2±0,2 electrodes were implanted, in 15% atrial, 52% RV and 52% LV electrodes. The procedures took 123±58 minutes and fluoroscopy dose was 5334±5390µGy/m2. There were 79 total occlusions of any segments and in addition, 51 subocclusive lesions needing venoplasty (table). 8 procedures were unsuccessful (9%), mostly due to failure to pass the occlusion. 3 patients (4%) had pocket hematoma not needing reintervention and one patient (1%) needed lead repositioning due to dislocation. There was no damage to any existing lead during the procedures. 89% of patients had a successful procedure without a complication needing reintervention.

Conclusions

Venoplasty is safe in subocclusive and occlusive venous stenosis and can be performed with high success using modern material potentially avoiding lead extraction or contralateral tunneling procedures.

Initial experience with a novel pulsed field ablation catheter for ablation of atrial fibrillation: procedural findings and acute safety

Funding Acknowledgements

Type of funding sources: None.

Background

Currently employed catheters for treatment of symptomatic atrial fibrillation (AF) leverage thermal energy to ablate the myocardium. Despite excellent acute success rates, the non-selective nature of thermal injury has been associated with frequent AF recurrences and complications such as pulmonary vein stenosis and thermal damage to adjacent structures. Recently, a novel, non-thermal ablative modality has been introduced for the treatment of AF: pulsed field ablation (PFA). The selective nature of PFA translates in the ability to perform full transmural lesions whilst sparing adjacent tissues and structures, making PFA an attractive solution to limitations faced with thermal energy sources. Although several pre-clinical studies investigated the safety and feasibility of PFA, limited reports have been published so far describing the clinical application of this novel catheter technology.

Purpose

In this study we present our initial experience with a pulsed field ablation catheter and describe procedural findings and acute safety of the first 68 patients treated at our center.

Methods

We investigated the first 68 patients treated for symptomatic AF at our center using pulsed field ablation between July 2021 and January 2022. Procedural findings at the time of ablation are presented. Procedure-related complications are reported. Qualitative analysis of electrograms and electrophysiological maps before and after ablation are also provided. Lastly, learning curves of operators who performed more than 10 procedures are described.

Results

Mean age of patients was 63.1±9.2 years, and most were men (57.4%). Most patients suffered from paroxysmal AF (79.4%). The median CHA2DS2-VASc score was 2.0 (1.0; 3.0) and mean left-atrium (LA) volume index was 33.0±8.3 ml/m2. All procedures were performed using conscious sedation. In 63/68 patients ablation of the PVI was performed and in 5/68 patients additional ablation of the left atrial posterior wall was performed. 3D electroanatomic mapping was performed during 10/68 procedures which lasted on average 107.3±15.5 min. Procedures where no mapping was performed lasted on average 48.5±20.7 min. Mean LA time was 39.9±19.0 min. Mean number of applications per pulmonary vein (PV) were 8.6±1.1. In all patients (100%) PVs were confirmed to be isolated. Four different operators performed the ablations: operator 1 performed 25/58 procedures (36.8%), operator 2 28/58 (41.2%), operator 3 9/58 (13.2%), and operator 4 6/58 (8.8%). The learning curves of both operator 1 and operator 2 showed negligible variation of performance over time (R2: Operator 1 = 0.181; Operator 2 = 0.078). The only complications reported were two cases of bleeding at the percutaneous access site of the femoral vein.

Conclusions

Our initial experience with a PFA catheter in 68 patients shows that PFA is a safe, quick, easy-to-learn, and effective ablation technique for the treatment of symptomatic AF.

Heart rate increase and inappropriate sinus tachycardia after cryoballoon pulmonary vein isolation for atrial fibrillation

BACKGROUND

Cryoballoon pulmonary vein isolation (PVI) is a common therapy for atrial fibrillation (AF). While moderately increased sinus rhythm heart rate (HR) after PVI has been observed, inappropriate sinus tachycardia (IST) is a rare phenomenon. We aimed to investigate the prevalence and natural history of an abnormal sinus HR response after cryoballoon PVI.

METHODS

We included 169/646 (26.2%) patients with AF undergoing PVI with available Holter recordings before and 3, 6 and 12 months after the procedure. Patients with AF on Holter monitoring were excluded. Mean HR increase ≥ 20 bpm or an IST-like pattern (mean HR > 90 bpm or > 80 bpm when beta-blocking agents were used) following PVI was categorised as abnormal sinus HR response.

RESULTS

Following PVI, mean HR ± standard deviation increased in the entire group from 63.5 ± 8.4 to 69.1 ± 9.9 bpm at 3 months (p < 0.001), and to 71.9 ± 9.4 bpm at 6 months (p < 0.001). At 12 months, mean HR was 71.2 ± 10.1 bpm (p < 0.001). Only 7/169 patients (4.1%) met criteria for abnormal sinus HR response: mean HR was 61.9 ± 10.6 bpm (pre-ablation), 84.6 ± 9.8 bpm (3 months), 80.1 ± 6.5 bpm (6 months) and 76.3 ± 10.1 bpm (12 months). Even at 12 months, mean HR was significantly different from that pre-ablation in this group (p = 0.033). However, in patients meeting IST-like pattern criteria, mean HR at 12 months was no longer significantly different from that pre-ablation.

CONCLUSION

Few patients had an abnormal sinus HR response after PVI. Peak HR was observed 3 months after PVI, but HR was still significantly increased 12 months post-ablation compared with pre-ablation. An IST-like pattern was rarely observed. In these patients, HR decreased to pre-ablation values within a year.

Gradually increasing impedance in patients with pacemakers and implantable defibrillators: a watchful waiting strategy

Funding Acknowledgements

Type of funding sources: None.

Introduction

Pacing impedance measurements are important in the surveillance of pacemaker and implantable cardioverter/defibrillator (ICD) devices. Whereas sudden changes in impedances can reflect lead fracture or isolation defects, gradually increasing impedances are thought to occur because of calcifications at the endomyocardial interface. In many cases, these leads are replaced prophylactically but this has not been studied systematically.

Purpose

We aimed to identify the outcome of right ventricular (RV) electrodes with high impedances that were left active in this single center study.

Methods

All patients in the electronic patient database were screened for impedances &gt;1200Ohms. 41,201 individual recordings led to 207 individual patients. 161 patients were excluded from the analysis due to sudden impedance increase, temporarily high impedances or wrong entry. Of the remaining 46 patients, baseline characteristics as well as pacing impedance, sensing values, pacing thresholds, and shock impedance in case of ICDs were recorded.

Results

There were 17 pacemaker and 29 ICD patients, 68 ± 15 years old, 70% were male. Glomerular filtration rate at baseline was 81 ± 22 ml/min/1.73m2. Baseline RV impedance was 597 ± 123Ohms. During follow-up impedances increased to 1875 ± 682Ohms (p &lt; 0,001). Pacing thresholds increased from 0,6 ± 0,4V to 3,0 ± 1,9V (p &lt; 0,001). Sensing remained stable. The median time from implant to  impedance rise &gt;1000Ohms was 5,5 (3,4-7)years and median follow-up thereafter 2,4 years (1,2-4,2). During follow-up, no intervention was performed for 33 leads (72%). No events occurred. 13 leads (28%) were replaced , 9 prophylactically (mostly because of ICD advisory leads), 3 because of high pacing thresholds and high percentage pacing and one lead because of noise oversensing, probably unrelated as it occurred 7 years after impedance increase.

Conclusions

A watchful waiting strategy appears to be a safe option for patients with ICDs and pacemakers with low percentage pacing. As impedance increase cannot be used for surveillance for imminent lead fracture, other means such as short interval counts and non-sustained oversensing have to be employed and should be combined with remote monitoring.

Erythropoietin treatment in patients with chronic heart failure: a meta-analysis

BACKGROUND

Anaemia is common in patients with chronic heart failure (HF), and erythropoiesis stimulating proteins (ESPs) are frequently used for its treatment. However, recent studies in patients with malignancies and renal failure have raised concerns about the safety of these agents.

OBJECTIVE

To determine whether treatment of anaemic patients with chronic HF with ESPs is associated with an effect on morbidity and mortality.

DATA SOURCES

A systematic literature search in Medline, the Cochrane Controlled Trials Register Database and ClinicalTrials.gov through July 2008 was performed.

STUDY SELECTION

Randomised clinical trials comparing the effect of ESP treatment with placebo or usual care in anaemic patients with HF were included.

RESULTS

Seven randomised controlled trials were identified that enrolled 650 patients, of whom 363 were treated with ESPs and 287 with placebo. ESP treatment had a significantly lower risk of HF hospitalisation (risk ratio (RR) = 0.59; 95% CI 0.41 to 0.86; p = 0.006).There was no significant difference in the mortality risk between the two groups (RR = 0.69; 95% CI 0.39 to 1.23; p = 0.21). No significant differences were observed in the occurrence of hypertension or venous thrombosis.

CONCLUSIONS

In chronic HF, treatment with ESPs is not associated with a higher mortality rate or more adverse events, whereas a beneficial effect on HF hospitalisation is seen. These outcomes are in contrast with studies in cancer and kidney disease, and support a large phase III morbidity and mortality trial of anaemia correction in patients with chronic HF.